The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV

Bibliographic Details
Main Author:	Hitchcock CA
Format:	Article
Language:	English
Published:	BMC 2005-12-01
Series:	Retrovirology

Similar Items

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
by: Thore Lorenzen
Published: (2010-08-01)

Mechanisms of CCR5 Agonist/Antagonist Inhibition of HIV-1 Entry and In Vitro Selection of Virus Resistant to Maraviroc
by: Ratcliff, Annette N.
Published: (2013)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01)

Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
by: Laura Ochoa-Callejero, et al.
Published: (2013-01-01)

In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
by: Pasqua Gramegna, et al.
Published: (2011-01-01)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists <it>in vitro </it>has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
by: Westby Mike, et al.
Published: (2011-11-01)

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
by: C Preston Neff, et al.
Published: (2011-01-01)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
by: Maximiliano Ruben Ferrero, et al.
Published: (2021-06-01)

Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
by: Borislav Savkovic, et al.
Published: (2012-01-01)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
by: José Joaquín Merino, et al.
Published: (2020-02-01)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
by: Jiang, X., et al.
Published: (2019)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
by: Stephanie M. Matt, et al.
Published: (2021-05-01)

The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial
by: J. Symons, et al.
Published: (2017-12-01)

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
by: Hualiang Jiang, et al.
Published: (2008-10-01)

Discovery of a Novel CCR5 Antagonist as an Effective Therapeutic Agent for Prostate Cancer
by: Ahmed, Tasrif
Published: (2010)

Maraviroc in Antiretroviral-Naïve HIV-1 Patients
by: Beniam Ghebremedhin
Published: (2012-01-01)

Maraviroc in Antiretroviral-Naïve HIV-1 Patients
by: Beniam Ghebremedhin
Published: (2012-01-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

Mechanism study of novel CCR5 antagonists and their potential as anti-HIV-1 microbicides
by: Kang, Yuanxi., et al.
Published: (2013)

CCR5 Antagonist and Agonist Binding Site Structures
by: Mills John, et al.
Published: (2005-12-01)

Antagonist of chemokine receptors CCR1 and CCR3
by: Ammit Alaina, et al.
Published: (2000-11-01)

HIV-1 Tropism Testing and Clinical Management of CCR5 Antagonists: Quebec Review and Recommendations
by: Cécile Tremblay, et al.
Published: (2013-01-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
by: Benoit Visseaux, et al.
Published: (2015-01-01)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
by: Becky Jubb, et al.
Published: (2019-12-01)

CCR5 and CXCR4 antagonist and agonist binding sites
by: Dratz Edward, et al.
Published: (2006-12-01)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

DEVELOPMENT OF ANTAGONISTS TARGETING CHEMOKINE RECEPTOR CCR5 AND THE CHEMOKINE RECEPTOR CCR5 – MU OPIOID RECEPTOR HETERODIMER
by: Arnatt, Christopher Kent
Published: (2013)

Pressure Mapping and Efficiency Analysis of an EPPLER 857 Hydrokinetic Turbine
by: Clark, Tristan
Published: (2017)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
by: Eric Lefebvre, et al.
Published: (2016-01-01)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
by: Sanjay Pujari MD, et al.
Published: (2018-02-01)

Association Among CCR5 Genotypes, CCR5 Expression, And In Vitro HIV Infection
by: John, Bangan
Published: (2013)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults
by: Anita Rachlis, et al.
Published: (2010-01-01)

Cannot write session to /tmp/vufind_sessions/sess_6cku9erg0djr6sgq2rgdjkm8n3